Hepatocytes lack GLP-1 receptor expression41 and therefore the potential mechanisms through which GLP-1 agonists exert an effect in NASH are likely to relate to improvements in weight and insulin resistance, coupled with reductions in mitochondrial dysfunction, proinflammatory mediators and lipotoxicity.41–43. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.